bluebird bio (NASDAQ: BLUE) and Aptose Biosciences (NASDAQ:APTO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Volatility & Risk

bluebird bio has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.

Valuation & Earnings

This table compares bluebird bio and Aptose Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
bluebird bio $35.43 million 239.77 -$335.64 million ($7.71) -20.34
Aptose Biosciences N/A N/A -$11.66 million ($0.52) -5.87

Aptose Biosciences has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

1.4% of Aptose Biosciences shares are owned by institutional investors. 3.0% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


This table compares bluebird bio and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
bluebird bio -1,281.01% -31.57% -26.37%
Aptose Biosciences N/A -136.61% -119.69%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for bluebird bio and Aptose Biosciences, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bluebird bio 2 8 14 0 2.50
Aptose Biosciences 0 0 3 0 3.00

bluebird bio currently has a consensus price target of $212.05, indicating a potential upside of 35.19%. Aptose Biosciences has a consensus price target of $7.33, indicating a potential upside of 140.44%. Given Aptose Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than bluebird bio.


Aptose Biosciences beats bluebird bio on 8 of the 13 factors compared between the two stocks.

bluebird bio Company Profile

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Aptose Biosciences Company Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with's FREE daily email newsletter.